Le Lézard
Classified in: Health
Subject: PER

Evolution Research Group Names Davide Molho President and CEO and Lori Thievon Wright Chairman of the Board


NEW PROVIDENCE, N.J., May 21, 2019 /PRNewswire/ -- Evolution Research Group, LLC (ERG) has appointed Davide Molho, D.V.M., as president and CEO. 

Evolution Research Group, LLC logo (PRNewsfoto/Evolution Research Group, LLC)

Lori Thievon Wright, who held the position for the past five years, will transition to chairman of the board and will remain an active board member. She is a co-founder of the company.

ERG is a leading independent clinical research site company serving pharmaceutical companies and clinical research organizations and has expertise in early- and late-stage pediatric and adult neuroscience drug development. 

Dr. Molho brings 25 years in the pharmaceutical services industry, most recently with Charles River Laboratories where he served as president and COO.

"ERG's customer-centric culture, extreme focus on quality and science, exceptional patient care, and high rate of employee engagement convinced me this is the right opportunity in which I can contribute to the success of clients developing new life saving drugs," Molho said.

"ERG has a solid foundation and tremendous ability to identify precisely the right patients for trials. I look forward to deepening this capability within existing therapeutic areas, expanding into new areas, and focusing on strategic growth."  

"The past five years have been incredibly rewarding and I feel so fortunate to have had some of the most talented and dedicated professionals in the industry join ERG during my tenure, culminating in Davide joining this month," Wright said. "The success of ERG has exceeded my wildest expectations and with Davide leading the strategy, I believe there is no limit to what this team can accomplish."

"Davide will continue the great leadership of the company as we pursue its next growth phase," ERG board member and partner at Linden Capital Partners, Michael Farah, said. "We commend Lori on building a world-class and market-leading organization, thank her for her years of dedication to ERG, and look forward to her continued involvement as chairman of the board."

About Evolution Research Group
Evolution Research Group, LLC comprises 13 wholly owned and operated clinical research units, and an established network of affiliated clinical research sites.  ERG conducts a wide range of simple and highly complex trials in specialized populations, including those suffering from psychiatric and neurological disorders, sleep disorders, addictions, acute and chronic pain, renal insufficiency, hepatic impairment, as well as normal healthy volunteers.

Learn more about ERG by visiting www.ergclinical.com

 

SOURCE Evolution Research Group, LLC


These press releases may also interest you

at 12:53
Sports nutrition and lifestyle brand Bucked Up launched its Babe by Bucked Up line last October with a desire to create supplements made by women, for women. With its official launch now six months underway, Babe has become a huge sensation and...

at 12:05
VirtualHealth is excited to share that its HELIOS platform was named the winner of a Bronze Stevie® Award in the Healthcare Technology Solution category in The 22nd Annual American Business Awards® today. More than 3,700 nominations were submitted...

at 12:02
On May 1, 2024, Toronto Public Health (TPH) will host Diverse Dialogues: Stigma & Breaking Barriers. The event will bring together distinguished speakers to explore the challenging and thought-provoking topic about how negative labels and biases...

at 11:56
As the demand for cosmetic procedures continues to rise, patients are seeking more advanced and effective options for achieving a youthful and rejuvenated appearance. In response to this, Dr. Ronald Demeo has introduced the Next Level Deep Plane Face...

at 11:50
Regulatory News: Median Technologies (FR0011049824, ALMDT, PEA-PME scheme eligible, "Median" or the "Company") today reported its 2023 consolidated annual financial results, as of December 31, 2023, and provided financial information (unaudited)...

at 11:34
At the Annual General Meeting of Vitrolife AB today, the following, amongst other things, was decided: Resolution in accordance with the Board's proposed dividend of SEK 1.00 per share for the financial year 2023. 29 April, 2024 was adopted as the...



News published on and distributed by: